Charles C. Wu - 20 Nov 2023 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: GYRE
Reported as of: 20 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Nov 2023, 19:20:00 UTC
Prior SEC filing: 01 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Ruoyu Chen, as attorney-in-fact for Charles C. Wu

Key filing fact

Charles C. Wu filed Form 4 for GYRE THERAPEUTICS, INC. (GYRE) on 22 Nov 2023.

Key facts

This page summarizes Charles C. Wu's Form 4 filing for GYRE THERAPEUTICS, INC. (GYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Nov 2023, 19:20.

Change

Previous filing in this sequence was filed on 01 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GYRE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +170,417
Change %
Price: $0.000000
Shares after: 170,417
Date: 20 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 170,417
Exercise price: $0.7500
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.

Footnote F2

These options are vested in full.